

PRODUCT INFORMATION




Olmesartan Medoxomil

Item No. 11614

CAS Registry No.: 144689-63-4
Formal Name: 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-carboxylic acid, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester

Synonym: CS 866
MF: C₂₉H₃₀N₆O₆
FW: 558.6
Purity: ≥98%
UV/Vis.: λ_{max}: 204, 256 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Olmesartan medoxomil is supplied as a crystalline solid. A stock solution may be made by dissolving the olmesartan medoxomil in the solvent of choice, which should be purged with an inert gas. Olmesartan Medoxomil is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of olmesartan medoxomil in these solvents is approximately 0.2, 20, and 30 mg/ml, respectively.

Olmesartan medoxomil is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, olmesartan medoxomil should first be dissolved in DMF and then diluted with the aqueous buffer of choice. Olmesartan medoxomil has a solubility of approximately 0.5 mg/ml in a 1:1 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Olmesartan medoxomil is an orally bioavailable prodrug form of olmesartan (Item No. 23412), a nonpeptide angiotensin II antagonist that is selective for the angiotensin 1 (AT₁) receptor over the AT₂ receptor.¹ Olmesartan medoxomil (0.1 mg/kg) inhibits the angiotensin II pressor response in normotensive rats. It reduces both systolic and diastolic blood pressure in fructose-fed rats, a model of insulin resistance, when administered at a dose of 10 mg/kg per day, as well as in chow-fed control animals when administered at a dose of 11.4 mg/kg per day.² Olmesartan medoxomil also inhibits increases in plasma levels of triglycerides and non-esterified fatty acids in fructose-fed rats. Formulations containing olmesartan medoxomil have been used in the treatment of hypertension.

References

1. Mizuno, M., Sada, T., Ikeda, M., *et al.* Pharmacology of CS-866, a novel nonpeptide angiotensin II receptor antagonist. *Eur. J. Pharmacol.* **285(2)**, 181-188 (1995).
2. Okada, K., Hirano, T., Ran, J., *et al.* Olmesartan medoxomil, an angiotensin II receptor blocker ameliorates insulin resistance and decreases triglyceride production in fructose-fed rats. *Hypertens. Res.* **27(4)**, 293-299 (2004).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/16/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM